Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hillstream BioPharma, Inc. - Common Stock (NQ: HILS )

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Hillstream BioPharma, Inc. - Common Stock

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
Via ACCESSWIRE
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
Via ACCESSWIRE
Hillstream BioPharma’s Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
Via ACCESSWIRE
Sidoti's January Micro-Cap Conference
Via ACCESSWIRE
Hillstream BioPharma Provides Business Review with Key Pipeline Updates
Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15 million Initial Public Offering on January 14, 2022 R&D Day to Review... 
From Hillstream BioPharma
Via AccessWire
SAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022
R&D Day on Thursday February 24, 2022 at 8:00 am ET to highlight emerging pipeline assets and anticipated milestones Business Review on Monday February 14, 2022 to highlight key program developments... 
From Hillstream BioPharma
Via AccessWire
Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression
BRIDGEWATER, NJ / ACCESSWIRE / February 1, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting... 
From Hillstream BioPharma
Via AccessWire
Hillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR and Computational Approaches to Advance The Hillstream Ferroptomic Atlas
Collaboration Aims to Identify Novel Chemogenetic Biomarker Profile of HSB-1216 for Solid Tumors Using CRISPR Mediated Genome Editing to Uncover Novel Targets and Gene Regulatory Networks in... 
From Hillstream BioPharma
Via AccessWire
Hillstream BioPharma Announces Closing of Initial Public Offering
BRIDGEWATER, NJ / ACCESSWIRE / January 14, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting... 
From Hillstream BioPharma
Via AccessWire
Hillstream BioPharma Announces Pricing of Initial Public Offering
BRIDGEWATER, NJ / ACCESSWIRE / January 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting... 
From Hillstream BioPharma
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.